Page 4 - Marek Ciszewski News Today

- FDA has been unable to travel to China to conduct the required site inspection resulting in delayed action on the BLA - - Junshi Biosciences and Coherus are actively engaged in ongoing discussions... | December 25, 2022

Junshi Biosciences and Coherus Share Update on the FDA Review of the Biologics License Application (BLA) for Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC) GlobeNewswire December 25, 2022 - FDA has been unable to travel to China to conduct the required site inspection resulting in delayed action on the...

Toripalimab in combination with chemotherapy was associated with significant improvements in PFS and OS compared with chemotherapy alone in patients with advanced NSCLC without EGFR/ALK mutations, regardless

Coherus to Launch CIMERLI™ (ranibizumab-eqrn) in the United States on October 3, 2022 - read this article along with other careers information, tips and advice on BioSpace

REDWOOD CITY, Calif., Aug. 29, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that...

Aravive Appoints Dr. Robert B. Geller as Chief Medical Officer - read this article along with other careers information, tips and advice on BioSpace

Aravive Appoints Dr. Robert B. Geller as Chief Medical Officer - Dr.... | July 5, 2022

46% Best Overall Response Rate in the ITT Population 63% Best Overall Response Rate in the sAXL/GAS6 Biomarker High Population 6-month Progression-Free Survival Rate in the ITT Population of 79%... | March 3, 2022

Aravive Announces First Patient Dosed in Phase 2 Study of Batiraxcept in Clear Cell Renal Cell Carcinoma Preliminary top line data anticipated throughout 2022 ... | January 31, 2022

Phase 1 trial is underway with topline results expected in the first half of 2022 Represents Landos’ seventh IND cleared overall and the second IND...